Celgene's R&D expenses surge in '14; Kolltan drops $86M IPO;

@FierceBiotech: AstraZeneca bolts together a top transatlantic team for CRISPR R&D. Report | Follow @FierceBiotech

@JohnCFierce: If you contrast the $NVS approach to CRISPR and $AZN's, $NVS seems much more focused. | Follow @JohnCFierce

@DamianFierce: Christoph Westphal's Flex Pharma prices an $86.4M IPO. News | Follow @DamianFierce

> Celgene ($CELG) put out its 2014 results today, noting that R&D expenses surged to $2.4 billion last year, up from $2.2 billion in 2013. Increased clinical trial activity was fingered for much of the increase. Celgene has one of the most active partnering groups in the industry. Release

> While the biotech IPO window remains open, not all companies can squeeze through. Kolltan Pharmaceuticals bowed out of its planned $86 million debut, designed to support its early-stage work on antibodies directed at receptor tyrosine kinases. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Abiomed shares hit all-time high due to strong demand for its Impella heart pumps. Article | Follow @FierceMedDev

@EmilyWFierce: Gilead zooms past AbbVie in hep C race with UnitedHealth deal. More | Follow @EmilyWFierce

> 2015 med tech IPO kick-off: Entellus exceeds expectations, while Presbia gets the deal done. Article

> China FDA approves Agilent's microarray scanner for in vitro diagnostics. Story

> Philips and Teva unveil new med tech incubator in Israel. Report

Pharma News

@FiercePharma: GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. More from FierceVaccines | Follow @FiercePharma

@EricPFierce: Do you want to know about the newest stents or heart valves approved by the FDA in 2014. Read on. Feature | Follow @EricPFierce

> Ex-FDA chief testifies against J&J in Risperdal liability case. More

> Looking to get out of the hot seat, Salix to restate financials for past 7 quarters. Story

> Gilead zooms past AbbVie in hep C race with UnitedHealth deal. Report

> Trans-Pacific trade talks on biologics not even close to agreement: USTR. Article

Vaccines News

> Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything. Article

> Pfizer's Prevenar price cut 'inadequate,' critics say. More

> Serum threatens Merck's Gardasil with low-cost competitor. Story

> First batch of GSK/NIH Ebola candidate shipped for Phase III trial in Liberia. Report

> GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. Item

Pharma Manufacturing News

> Chinese Pharmacopoeia venture up and running as safety push continues. More

> AmerisourceBergen again reports big leaps in revenue and earnings. Report

> GSK awards contract for API plant in Scotland. News

> International regulators offer to help India build expertise. Story

> Ranbaxy earnings pulled back down by manufacturing issues. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.